Guerbet, a key player in contrast agents and medical imaging solutions, long-standing partner of European Congress of Radiology (ECR), is proud to contribute with its program to this year’s ECR theme “Next Generation Radiology”.
Leader in MRI, Guerbet will unveil significant advances in Diagnostic Imaging with the approval in Europe of Elucirem™ (Gadopiclenol) the next generation of GBCA* from Guerbet and a disruptive Artificial Intelligence program.
Guerbet, a pioneer in Diagnostic Imaging, is distinguished by its unwavering commitment to innovation and quality in medical imaging solutions offered to radiologists and patients Elucirem™ (Gadopiclenol), a contrast agent with high relaxivity enabling less gadolinium use newly approved in Europe will be officially presented to European radiologists. With strong clinical evidence [1], Elucirem™(Gadopiclenol) offers a significant advance in macrocyclic contrast agents [2], guaranteeing high-quality image while minimizing impact on patients and the environment [3].
Guerbet’s presence at the European Congress of Radiology (ECR) thus testifies to its commitment to redefining medical imaging standards, placing the company at the forefront of innovations in medical imaging worldwide.
“Guerbet remains committed to pushing back the frontiers of medical imaging, offering innovative solutions that redefine standards of care while integrating environmentally friendly practices”, concludes Philippe Bourrinet, Guerbet VP Medical Director.
Guerbet is positioning itself as a main player in AI in radiology.
The AI program will explore Guerbet’s major advances in this field, highlighting crucial topics such as MRI detection of prostate cancer, the use of deep learning-based algorithms to detect focal liver lesions, and a new approach with AI for pancreatic cancer detection.
To introduce the ECR 2024, Philippe Bourrinet (VP Medical Director) and Faizal Mansor (Global Head of Marketing) will be interviewed on February 28 at the opening of the Congress by the European Society of Radiology: Less is more in contrasted MRI: benefits for radiologists, radiographers, patients & the planet. – ESR Connect (myesr.org).
We look forward to seeing you at ECR 2024!
“We are incredibly excited to welcome Guerbet as a key partner at this year’s congress. Their approach to AI and innovation is perfectly aligned with this year’s congress theme of Next Generation Radiology”, stated Carlo Catalano, ECR 2024 Congress President.
Below you can find the full program of Guerbet Symposia at ECR 2024:
MRI Symposium
February 29th. 12:30 pm – 13:30 pm
Central European Time (CET)
Elucirem™ (Gadopiclenol) – Clinical evidence of the innovative macrocyclic high-relaxivity low-gadolinium-dose GBCA
Speakers: Laurie Loevner, Hospital of the University of Pennsylvania – Philadelphia/ USA; Boris Nicolas Bloch, UMass Medical School – Worchester/USA and Jean-Sébastien Raynaud, Guerbet/France
AI Symposium
March 1st. 12:30 pm – 13:30 pm
Central European Time (CET)
Oncological imaging: How to improve detection with AI
Moderator: Pr. Carlo Quattrocchi, Trento University, Trento/Italy
Speakers: Anindo Saha, Radboud University Medical Center, Nijmegen /Netherlands; Pr. Maxime Ronot, Beaujon University Hospital, AP-HP /France and Clément Abi-Nader, AI medical imaging scientist, Guerbet /France.
* GBCA: gadolinium based contrast agent
[1] Bendszus et al. MRI Gadolinium-Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs. J Magn Reson Imaging 2024.
[2] Loevner et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Invest Radiol 2023.
[3] Kuhl et al. Efficacy and Safey of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology 2023.
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,700 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.
Forward-looking statements
This press release may contain forward-looking statements based on the assumptions and forecasts of Guerbet Group management. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s future results, financial situation, growth and performance and those presented by these forward-looking statements. These factors include those that are mentioned in Guerbet’s public documents and available on its website https://www.guerbet.com The Group expressly disclaims any obligation to publish an update or revision of the forward-looking statements contained in this press release to reflect future events or developments.
Contacts presse:
Guerbet: Claire Lauvernier, Communication Director
+33.6.79.52.11.88 / [email protected]